<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035879</url>
  </required_header>
  <id_info>
    <org_study_id>M2982-20920</org_study_id>
    <nct_id>NCT01035879</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes</brief_title>
  <official_title>Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at
      three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4
      weeks in patients that are treatment-naive or taking a single anti-diabetic medication
      (non-TZD, non-injectable).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 100 patients will be randomized in this study, 20 to each of of the three
      MBX-2982 treatment groups, 20 to placebo, and 20 to the sitagliptin group. Patients will be
      taking 3 tablets and 1 capsule daily. This sample size provides the minimum number expected
      to ensure a power of at least 80% to detect a 20% decrease in the weighted mean glucose level
      associated with an extended mixed meal tolerance test (with 2 standardized meals) relative to
      placebo after 4 weeks of daily treatment with MBX-2982, assuming a drop-out rate of 20% and a
      common SD of 25%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of MBX-2982 on additional glycemic parameters.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>MBX-2982 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2982 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-2982 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2982</intervention_name>
    <description>tablets and capsule once daily</description>
    <arm_group_label>MBX-2982 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2982</intervention_name>
    <description>tablets and capsule once daily</description>
    <arm_group_label>MBX-2982 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-2982</intervention_name>
    <description>tablets and capsule once daily</description>
    <arm_group_label>MBX-2982 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>tablets and capsule once daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablets and capsule once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of type 2 diabetes of at least 3 months duration

          -  Treatment-naïve (not on any anti-diabetic medication) or treated with a single
             anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone
             or rosiglitazone)

          -  HbA1c 7.0-8.5% (inclusive) at screening

          -  BMI ≥ 26 kg/m2 for patients recruited from U.S or Georgia or ≥ 22 kg/m2 for patients
             recruited from India

        Exclusion Criteria:

          -  Any history of type 1 diabetes or diabetic ketoacidosis

          -  History of major upper GI surgery

          -  Evidence or history of clinically significant GI illness including dyspepsia, PUD,
             nausea, diarrhea, malabsorption, etc.

          -  History of outpatient insulin use within last 1 year (insulin use while hospitalized
             is acceptable)

          -  Weight loss &gt; 10 pounds (4.5 kg) in the 3 months prior to screening visit or use of
             weight loss medications (prescription or OTC) within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Roberts, MD</last_name>
    <role>Study Director</role>
    <affiliation>Metabolex, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Alliance Against Diabetes</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research, Inc., a Cetero Research Co.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthy Life Clinical Diagnostic Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgian Diabetes Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medulla Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharti Research Institute of Diabetes and Endocrinology</name>
      <address>
        <city>Karnal</city>
        <state>Haryana</state>
        <zip>132001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Thyroid Hormone Research Institute Pvt Ltd</name>
      <address>
        <city>Indore</city>
        <state>M.p.</state>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Endocrinology &amp; Diabetes Centre</name>
      <address>
        <city>Ramdaspeth</city>
        <state>Nagpur</state>
        <zip>10</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gokula Metropolis Research, MS Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisys Clinisearch India Pvt Ltd</name>
      <address>
        <city>Bangalore</city>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hormone Care Research Centre</name>
      <address>
        <city>Ghaziabad</city>
        <zip>201002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Endocrinology &amp; Diabetes Research Centre</name>
      <address>
        <city>Malleshwaram</city>
        <zip>560 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <disposition_first_submitted>February 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

